Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "Monolith"
31 3월 2014 - 10:15PM
Marketwired
Decision Diagnostics Announces Posting and Airing of Its New
GenStrip Commercial Titled "Monolith"
The GenStrip(TM) Was First Shipped in 2013 as an Inexpensive
Alternative for Users of J&J LifeScan OneTouch(R), Ultra(R),
Ultra2(R), and Ultra Mini(R)
LOS ANGELES, CA--(Marketwired - Mar 31, 2014) - Decision
Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales,
service and regulatory processes agent for the Shasta GenStrip™,
the Green Glucose Test Strip, specifically designed to work with
the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of
glucose testing meters, today announced that its Pharma Tech
Solutions subsidiary has completed and will air in many regions in
the U.S. its new commercial video titled "GenStrip: Monolith." The
video is available for viewing at:
http://shastagenstrip.com/winter_ad.html or
http://youtu.be/10sOaLxGvjQ
The company will publish a media schedule for GenStrip:
"Monolith" just as soon as all previously purchased commercial
spots for the GenStrip "A Patchwork of Life" spots are completed.
The new GenStrip commercial will be played in most metropolitan
areas beginning April 5, 2014. Time has also been booked from a
nationwide service for the local hours of 1:00 pm through 6:00 pm.
However, the bulk of the 12,500 purchased commercial plays for
thirty days beginning April 5, 2014 will be via saturated cable
television buys during late at night hours, a time tested method
used for diabetes and over-the-counter pharmaceutical products.
DECN is also a leading provider of prescription and
non-prescription diagnostics, home testing products for the
chronically ill and a premier developer of revolutionary cell phone
centric e-health products and technologies. DECN's
GenStrip™ product was cleared by the U.S. FDA in November 2012, and
after several successful long running legal battles with a division
of Johnson & Johnson, Genstrip was finally introduced to the
market in late 2013 as a lower cost (60%) alternative for
user/owners of Johnson and Johnson LifeScan OneTouch® Ultra®,
Ultra2® and Ultra Mini® glucose meters.
Forward-Looking
Statements: This release contains forward-looking statements
about our business or financial condition that reflect our
assumptions and beliefs based on information currently available.
We can give no assurance that the expectations indicated by such
forward-looking statements will be realized. There may be other
risks and circumstances that we are unable to predict. When used in
this release, words such as "believes," "expects," "forecasts,"
"intends," "projects," "plans," "anticipates," "estimates," "will"
and similar expressions are intended to identify forward-looking
statements, although there may be certain statements not
accompanied by such expressions.
For further information about Shasta GenStrip, please visit the
company's Web Sites: http://www.decisiondiagnostics.com or
http://www.shastagenstrip.com or www.pharmatechdirect.com.
GenStrip™ test strips are a product of Pharma Tech Solutions,
Inc. and are not manufactured, distributed, endorsed, or approved
by, nor associated with, LifeScan®, Inc. a Johnson & Johnson®
Company, manufacturers and distributors of the OneTouch® Ultra®
Family of meters and OneTouch® Ultra® test strips.
Contact: Decision Diagnostics Corp. Keith Berman (805) 446-2973
info@decisiondiagnostics.com
Decision Diagnostics (CE) (USOTC:DECN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Decision Diagnostics (CE) (USOTC:DECN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024